Skip to content
Sign inOpen the app
Artwork for Inflexion Point
Inflexion Point · Today · 24 min

From carve-out to pan-European platform with CNX Therapeutics

Most pharma businesses are built on new drugs. CNX Therapeutics was built on the ones big pharma had overlooked. Carved out of US group Sunovion in 2021 with a single product, it now spans more than 60 countries, has grown to 25 products, and become the first UK pharmaceutical company to earn B Corp status. 💊 In this episode, CNX CEO Guy Clark joins host Tim Smallbone and Inflexion's Christian Fellowes to explore how a thesis first sketched on a napkin became a pan European platform, why so many effective medicines never reach the patients who need them, and how you scale from 17 people to nearly 70 without losing your culture.

0:00-24:45
Play in podnod

transcript

No transcript — this publisher did not publish one.

show notes

Most pharma businesses are built on new drugs. CNX Therapeutics was built on the ones big pharma had overlooked. Carved out of US group Sunovion in 2021 with a single product, it now spans more than 60 countries, has grown to 25 products, and become the first UK pharmaceutical company to earn B Corp status. 💊

In this episode, CNX CEO Guy Clark joins host Tim Smallbone and Inflexion's Christian Fellowes to explore how a thesis first sketched on a napkin became a pan European platform, why so many effective medicines never reach the patients who need them, and how you scale from 17 people to nearly 70 without losing your culture.

more episodes

All episodes